Can a heart failure drug effectively treat a lethal form of ovarian cancer? Scientists hope the answer is 'yes'
Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...
Unlocking new insights into hereditary ovarian cancer risk
Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...
News Medical on MSN6d
Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancer
Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...
Armed robbery in Revesby7d
First Real-World Proof: Olaparib for New Ovarian Cancer
Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...
Rolling Out11d
Treatment options for women with ovarian cancer
Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...
Cure Today28d
FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer
Low-grade serous ovarian cancer is highly recurrent and less sensitive to chemotherapy compared with high-grade serous ovarian cancer and approximately 6,000 to 8,000 women in the United States — as ...
Business Insider29d
FDA To Decide On Verastem's Avutometinib & Defactinib For A Subtype Of Serous Ovarian Cancer In June
The company's New Drug Application seeking accelerated approval for Avutometinib in combination with Defactinib for the treatment of recurrent KRAS mutant low-grade serous ovarian cancer has been ...